Life Sciences / Regulatory Brief 🧬

📌 Navigate

📊 Exec Summary

The FDA approved two first-in-class drugs in the same week — an oral IL-23 blocker for psoriasis and the first treatment for PBC-related itch — while two Nature papers converged on multi-organ axes for neurodegeneration, and Perplexity launched a consumer health AI that connects real patient data to specialized agents.

Five things moved in life sciences / regulatory this week:

1. FDA approves Icotyde (icotrokinra) — first oral peptide IL-23 receptor blocker for plaque psoriasis; 70% IGA 0/1 at week 16
2. FDA approves Lynavoy (linerixibat) — first drug for cholestatic pruritus in PBC; rapid onset at week 2
3. Gut-brain and liver-brain axes converge — two Nature papers link peripheral organs to Alzheimer's and cognitive aging
4. Perplexity Health launches — consumer health AI connecting 1M+ provider records with specialized agents
5. EU AI Act enforcement still incomplete — full enforcement August 2, 2026

The pattern: Oral delivery proved it can match injectable efficacy in autoimmune disease, multi-organ axis biology moved from hypothesis to published evidence, consumer health AI crossed from chatbot to data-connected agent (a product launch, not a regulatory event), and regulatory enforcement on both sides of the Atlantic remained aspirational rather than operational.

1. FDA approves Icotyde (icotrokinra) — first oral IL-23 receptor blocker for plaque psoriasis

TL;DR: The FDA approved Icotyde (icotrokinra) on March 18, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and pediatric patients 12+ years weighing 40+ kg, marking a modality milestone that proves oral biologics can match injectable efficacy.

What happened

• FDA approved March 18, 2026; J&J (Janssen) is the developer
• Icotrokinra is an oral, targeted IL-23 receptor antagonist — first in its class
• Approved for adults and adolescents >=12yr/>=40kg candidates for systemic therapy or phototherapy
• Based on the Phase 3 ICONIC clinical development program (multiple randomized, double-blind trials, 2,500+ patients)

Primary source --> J&J Investor Relations: FDA approval of Icotyde Medscape: FDA Approves Icotrokinra · AJMC coverage

The non-obvious point

The modality milestone matters more than the indication.

• Oral delivery of a targeted peptide that matches injectable biologic efficacy is the real precedent. If IL-23 pathway blockade works orally, the same approach could extend to other autoimmune targets (IL-17, IL-6, TNF pathway) — dramatically expanding the addressable market for oral biologics.
• For AI-driven drug design: the peptide engineering that made icotrokinra orally bioavailable is exactly the kind of challenge where structure-prediction models (AlphaFold-class) and generative chemistry could accelerate analogue exploration. Expect computational teams to study the ICONIC structural data closely.
• Absence: no companion diagnostic or biomarker strategy was included in the approval. This is standard for psoriasis but notable as the industry moves toward precision dermatology.

What to watch

• J&J's label-expansion filing for psoriatic arthritis — expected H2 2026
• Competitor oral biologic programs (AbbVie, Bristol Myers Squibb) entering Phase 3 readouts

2. FDA approves Lynavoy (linerixibat) — first treatment for cholestatic pruritus in PBC

TL;DR: The FDA approved Lynavoy (linerixibat) on March 19, an IBAT inhibitor and the first drug approved in the U.S. specifically for cholestatic pruritus in primary biliary cholangitis, with the GLISTEN trial showing rapid onset (week 2) and sustained improvement over 24 weeks.

What happened

• FDA approved March 19, 2026; GSK is the developer (licensed to Alfasigma for certain markets)
• Linerixibat is an ileal bile acid transporter (IBAT) inhibitor — oral, small molecule
• First-in-indication approval: no prior drug was approved for PBC-related itch in the U.S.
• GLISTEN trial met primary and key secondary endpoints
• Cholestatic pruritus affects up to 89% of PBC patients

Primary source --> GSK: Lynavoy approved by the US FDA Drugs.com: FDA Approves Lynavoy · HCPLive coverage

The non-obvious point

First-in-indication approvals in rare disease create regulatory precedent that extends far beyond the disease itself.

• PBC is rare (~130K diagnosed in the U.S.) but the IBAT mechanism has implications for any bile-acid-mediated condition — including NASH/MASH, cholestatic liver diseases, and potentially bile-acid-related GI conditions. Linerixibat's success validates the target for label expansion.
• The 61% diarrhea rate is the GI-tolerability problem that every bile-acid-pathway drug must solve. AI-driven formulation optimization (controlled release, site-specific delivery) could reduce this — an immediate application for computational drug design.
• For regulatory strategy: the rapid-onset (week 2) endpoint design is worth studying. GLISTEN's willingness to anchor on early timepoints for a chronic condition compressed the development timeline and could serve as a template for other symptom-driven rare-disease programs.

What to watch

• GSK's IBAT inhibitor pipeline for additional bile-acid-pathway indications — expected updates Q2-Q3 2026
• Competing PBC treatment programs from Intercept Pharmaceuticals and CymaBay

3. Gut-brain and liver-brain axes converge in Alzheimer's and aging research

TL;DR: Derek Lowe highlighted two Nature papers published the same week linking gut bacteria and liver metabolites to brain cognition and Alzheimer's, establishing multi-organ axis biology as converging evidence for peripheral-organ influences on neurodegeneration.

What happened

• Paper 1: Nature study linking gut microbiome composition to cognitive decline and Alzheimer's pathology markers
• Paper 2: Nature study demonstrating liver-derived metabolites crossing the blood-brain barrier and modulating neural function
• Derek Lowe covered both in consecutive In the Pipeline posts (March 18-19)
• The convergent timing from independent research groups strengthens the multi-organ-axis hypothesis

Primary source --> In the Pipeline: From Gut Bacteria Up to the Brain In the Pipeline: Beneficial Effects From the Liver to the Brain · Nature (gut-brain)

The non-obvious point

Multi-organ axis biology is graduating from hypothesis to actionable target space, and computational biology is the enabler.

• Traditional drug discovery treats diseases organ-by-organ. These papers demand multi-tissue models — exactly the kind of complex system where graph neural networks and multi-omics integration models add value that single-target approaches cannot.
• For AI-in-biotech: the opportunity is not just target identification but cross-tissue interaction modeling. A foundation model trained on multi-organ transcriptomic data could predict downstream effects of gut or liver interventions on CNS endpoints. This is a differentiated research direction for biotech AI companies.
• The Alzheimer's connection makes this commercially important, not just scientifically interesting. If gut or liver interventions can modify Alzheimer's risk, the addressable market dwarfs current microbiome therapeutics.

What to watch

• Follow-up mechanistic studies identifying specific bacterial species or liver metabolites as drug targets
• Biotech companies announcing multi-organ-axis programs — watch Recursion, Insitro, and Flagship Pioneering portfolios

4. Perplexity Health launches consumer health AI with connected data and specialized agents

TL;DR: Perplexity launched Perplexity Health in the U.S. for Pro and Max subscribers, a consumer health AI platform that connects medical records from 1M+ providers and personal health devices (Fitbit, Google Fit, Cronometer, Clue), with specialized agents for nutrition, sleep, and personalized health plans.

What happened

• Launched March 20, 2026 in the U.S. for Perplexity Pro and Max subscribers
• Connects medical records from 1M+ providers via secure integrations
• Integrates device data: Fitbit, Google Fit, Cronometer, Clue, and more
• Includes specialized AI agents for nutrition, sleep, chronic condition management, and fitness optimization
• Integrated with Perplexity Computer for actionable workflows (not just Q&A)

Primary source --> Perplexity Health launch TLDR AI coverage

The non-obvious point

This is the first consumer health AI that treats health data as a connected graph rather than isolated queries.

• The combination of medical records + device data + specialized agents creates a longitudinal health context that most health AI tools lack. Previous health chatbots answered questions about symptoms; Perplexity Health can reason across your medical history, daily activity, and stated goals.
• For biotech: watch whether Perplexity Health's user base generates the kind of real-world evidence (RWE) data that pharmaceutical companies need for post-market studies. If millions of users connect their records and share outcomes, the platform becomes a data asset.
• Regulatory question: Perplexity Health is launched as a consumer product, not a medical device. But specialized agents that "help you reach specific goals" and "manage chronic conditions" edge into clinical decision support territory. Watch for FDA Digital Health Center of Excellence guidance.

What to watch

• FDA Digital Health Center of Excellence position on consumer AI health agents — expected guidance H2 2026
• Whether Perplexity Health publishes validation studies on agent recommendation accuracy

5. EU AI Act enforcement infrastructure still incomplete — 8 of 27 member states ready

TL;DR: The European Parliament published an enforcement briefing on March 18 showing only 8 of 27 EU member states have designated the required enforcement authorities, with full Commission enforcement powers activating on August 2, 2026 — creating a five-month gap between compliance obligations and enforcement capacity.

What happened

• EU Parliament Think Tank published comprehensive enforcement briefing on March 18, 2026
• Only 8 of 27 member states have established single points of contact with the Commission
• Full enforcement powers enter into application August 2, 2026
• The Commission proposed expanding its AI Office authority to supervise GPAI models and AI systems in very large online platforms (via the Digital Omnibus on AI proposal, November 2025)
• Second Draft Code of Practice on AI-generated content marking/labeling was published in March

📎 Sources

Sources of truth

Also consider reading